Pathogenic pathways and therapeutic targets of inflammation in heart diseases: A focus on Interleukin‐1

Abstract

AbstractBackgroundAn exuberant and dysregulated inflammatory response contributes to the development and progression of cardiovascular diseases (CVDs).MethodsThis narrative review includes original articles and reviews published over the past 20 years and found through PubMed. The following search terms (or combination of terms) were considered: “acute pericarditis,” “recurrent pericarditis,” “myocarditis,” “cardiac sarcoidosis,” “atherosclerosis,” “acute myocardial infarction,” “inflammation,” “NLRP3 inflammasome,” “Interleukin‐1” and “treatment.”ResultsRecent evidence supports the role of inflammation across a wide spectrum of CVDs including myocarditis, pericarditis, inflammatory cardiomyopathies (i.e. cardiac sarcoidosis) as well as atherosclerotic CVD and heart failure. Interleukins (ILs) are the signalling mediators of the inflammatory response. The NACHT, leucine‐rich repeat and pyrin‐domain containing protein 3 (NLRP3) inflammasome play a key role in producing IL‐1β, the prototypical pro‐inflammatory cytokine involved in CVDs. Other pro‐inflammatory cytokines (e.g. tumour necrosis factor) have been implicated in cardiac sarcoidosis. As a proof of this, IL‐1 blockade has been proven efficacious in pericarditis and chronic coronary syndrome.ConclusionTailored strategies aiming at quenching the inflammatory response have emerged as promising to treat CVDs. In this review article, we summarize recent evidence regarding the role of inflammation across a broad spectrum of CVDs. We also review novel evidence regarding targeted therapeutic strategies.